NCT04648254

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: Qurient Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.

Conditions

• Solid Tumor
• Advanced Cancer
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	Q702	The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.

Timeline

• Start date: 2020-11-18
• Primary completion: 2025-12-23
• Completion: 2025-12-23
• First posted: 2020-12-01
• Last updated: 2025-12-30

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study